fda compounding semaglutide warning letters october 2025 Troubling Findings in Study of GLP-1 Compounders FDA warns telehealth companies over

Overall, 12.7% of users were newly diagnosed with a nutritional deficiency at 6 months and over 22% by 12 months

Early data showed approximately 22% weight loss in 36 weeks, which extrapolates to potentially 25% or more at 68 weeks

A network meta-analysis published recently confirmed this pattern, finding that retatrutide demonstrated greater absolute weight reduction compared to tirzepatide (retatrutide: MD -16.34 kg vs tirzepatide: MD -11.82 kg)

collect additional data on comorbid health conditions

Another study in rodents showed similar results, whilst also highlighted the reversal of steatohepatitis in female mice [59]

Dolores Catania While chatting with Andy Cohen in April 2023, the star of "The Real Housewives of New Jersey" said she had been taking Ozempic